Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
By Josh Beckerman
Ono Pharmaceutical completed its purchase of Deciphera Pharmaceuticals for about $2.4 billion.
Nasdaq halted Deciphera shares late Monday, seeking additional information. Ono said Tuesday that it successfully completed a $25.60-a-share tender offer for the cancer-focused biopharmaceutical company. The deal was announced in April.
Deciphera reported a fourth-quarter loss of 54 cents a share on total revenue of $48.3 million in February.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 11, 2024 13:24 ET (17:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks